Peregrine Pharmaceuticals to Present at the 27th Annual ROTH Conference
March 02 2015 - 04:00PM
Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP), a
biopharmaceutical company focused on advancing bavituximab, a novel
immuno-oncology antibody targeting the highly immunosuppressive
phosphatidylserine (PS) signaling pathway, towards
commercialization and providing integrated cGMP clinical and
commercial bio-manufacturing services, announced that Steven W.
King, president and chief executive officer, will present a company
update at the 27th Annual ROTH Conference on Monday, March 9th,
2015 at 10:00 AM Pacific Time (1:00 PM Eastern Time) at The
Ritz-Carlton Laguna Niguel in Dana Point, California.
Peregrine's presentation at the ROTH conference will be
webcast live and available for replay for 30 days at:
http://ir.peregrineinc.com/events.cfm
About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company
with a pipeline of novel drug candidates in clinical trials for the
treatment and diagnosis of cancer. The company's lead
immuno-oncology candidate, bavituximab, is in Phase III development
for the treatment of second-line non-small lung cancer (the
"SUNRISE trial") along with several investigator-sponsored trials
evaluating other treatment combinations and additional oncology
indications. The company is also advancing a molecular imaging
agent, 124I-PGN650, in an exploratory clinical trial for the
imaging of multiple solid tumor types. Peregrine also has in-house
cGMP manufacturing capabilities through its wholly-owned subsidiary
Avid Bioservices, Inc. (www.avidbio.com), which provides
development and biomanufacturing services for both Peregrine and
third-party customers. Additional information about Peregrine can
be found at www.peregrineinc.com.
CONTACT: Christopher Keenan
Peregrine Pharmaceuticals, Inc.
(800) 987-8256
info@peregrineinc.com
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Mar 2023 to Mar 2024